Burning Rock Biotech annual stock-based compensation
2020
2021
2022
2023
2024
2025
Burning Rock Biotech Stock-Based Compensation Growth & History (BNR)
Burning Rock Biotech's stock-based compensation was $2.0M for fiscal 2025.
View full Burning Rock Biotech company overviewBurning Rock Biotech annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.0M | −$19.3M | −90.69% |
| 2024 | 2024-12-31 | $21.3M | −$15.4M | −41.94% |
| 2023 | 2023-12-31 | $36.7M | −$10.7M | −22.49% |
| 2022 | 2022-12-31 | $47.4M | $3.1M | +6.90% |
| 2021 | 2021-12-31 | $44.3M | $17.8M | +66.95% |
| 2020 | 2020-12-31 | $26.5M | — | — |
Burning Rock Biotech stock-based compensation trends
Over the last five fiscal years, Burning Rock Biotech's stock-based compensation decreased from $26.5M to $2.0M, a change of −$24.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Burning Rock Biotech source filings ↗